1. Field of the Invention
The present invention relates to electrosurgical methods and devices for global endometrial ablation in a treatment of menorrhagia. More particularly, the present invention relates to applying radiofrequency current to endometrial tissue by means of capacitively coupling the current through an expandable, thin-wall dielectric member enclosing an ionized gas.
A variety of devices have been developed or proposed for endometrial ablation. Of relevance to the present invention, a variety of radiofrequency ablation devices have been proposed including solid electrodes, balloon electrodes, metalized fabric electrodes, and the like. While often effective, many of the prior electrode designs have suffered from one or more deficiencies, such as relatively slow treatment times, incomplete treatments, non-uniform ablation depths, and risk of injury to adjacent organs.
For these reasons, it would be desirable to provide systems and methods that allow for endometrial ablation using radiofrequency current which is rapid, provides for controlled ablation depth and which reduce the risk of injury to adjacent organs. At least some of these objectives will be met by the invention described herein.
2. Description of the Background Art
U.S. Pat. Nos. 5,769,880; 6,296,639; 6,663,626; and 6,813,520 describe intrauterine ablation devices formed from a permeable mesh defining electrodes for the application of radiofrequency energy to ablate uterine tissue. U.S. Pat. No. 4,979,948 describes a balloon filled with an electrolyte solution for applying radiofrequency current to a mucosal layer via capacitive coupling. U.S. 2008/097425, having common inventorship with the present application, describes delivering a pressurized flow of a liquid medium which carries a radiofrequency current to tissue, where the liquid is ignited into a plasma as it passes through flow orifices. U.S. Pat. No. 5,891,134 describes a radiofrequency heater within an enclosed balloon. U.S. Pat. No. 6,041,260 describes radiofrequency electrodes distributed over the exterior surface of a balloon which is inflated in a body cavity to be treated. U.S. Pat. No. 7,371,231 and U.S. 2009/054892 describe a conductive balloon having an exterior surface which acts as an electrode for performing endometrial ablation. U.S. Pat. No. 5,191,883 describes bipolar heating of a medium within a balloon for thermal ablation. U.S. Pat. No. 6,736,811 and U.S. Pat. No. 5,925,038 show an inflatable conductive electrode.
The following presents a simplified summary of some embodiments of the invention in order to provide a basic understanding of the invention. This summary is not an extensive overview of the invention. It is not intended to identify key/critical elements of the invention or to delineate the scope of the invention. Its sole purpose is to present some embodiments of the invention in a simplified form as a prelude to the more detailed description that is presented later.
The present invention provides methods, systems and devices for evaluating the integrity of a uterine cavity. The uterine cavity may be perforated or otherwise damaged by the transcervical introduction of probes and instruments into the uterine cavity. If the uterine wall is perforated, it would be preferable to defer any ablation treatment until the uterine wall is healed. A method of the invention comprises introducing transcervically a probe into a patient's uterine cavity, providing a flow of a fluid (e.g., CO2) through the probe into the uterine cavity and monitoring the rate of the flow to characterize the uterine cavity as perforated or non-perforated based on a change in the flow rate. If the flow rate drops to zero or close to zero, this indicates that the uterine cavity is intact and not perforated. If the flow rate does not drop to zero or close to zero, this indicates that a fluid flow is leaking through a perforation in the uterine cavity into the uterine cavity or escaping around an occlusion balloon that occludes the cervical canal.
Embodiments herein provide a system for treating uterine tissue, including a thin conformable wall at least partially surrounding an interior chamber and having a shape for positioning in a uterine cavity, the wall capable of non-expanded and expanded shapes; and an indicator mechanism operatively coupled to the wall and configured to indicate non-expanded and expanded shapes of the wall.
In embodiments, the interior chamber is fluid-tight, the wall is at least partly a dielectric, and/or the wall comprises an energy delivery surface for delivering ablative energy to uterine tissue. The wall may, for example, deliver RF current for ablating tissue.
An indicator mechanism may be provided to indicate threshold expansion of the wall for delivering RF current to the tissue. The indicator mechanism may be coupled to a controller, with threshold expansion of the wall enabling an RF source to deliver RF current to the tissue.
The indicator mechanism may be coupled to a controller and an absence of threshold expansion of the wall causes the controller to disable the RF source to prevent the delivery of RF current to the wall.
In embodiments, the non-expanded shape is configured for constraining in a bore in a sleeve.
The expanded shape may have a triangular configuration for contacting endometrial tissue about the uterine cavity, or a plurality of partially expanded shapes for contacting endometrial tissue in varied shapes of uterine cavities, or a plurality of partially expanded shapes for contacting endometrial tissue in varied dimension uterine cavities, as examples.
Embodiments include a frame having at least one spring element in the interior chamber biasing the wall toward the expanded shape. The indicator mechanism may be coupled to the frame and indicate expansion of the wall by movement of the frame. In embodiments, the indicator mechanism comprises an indicator member that indicates the axial relationship between first and second axially-extending frame elements.
The indicator mechanism may provide at least one of visual, aural or tactile indication.
Embodiments may additionally include an energy delivery controller, with the wall having an energy delivery surface coupled to the energy delivery controller and for delivering ablative energy to uterine tissue, and wherein the indicator mechanism comprises an electrical sensor operatively coupled to the energy delivery controller such that the controller operates the energy delivery surface responsive to a signal from the indicator mechanism.
The wall may include an energy delivery surface coupled to the energy delivery controller and for delivering ablative energy to uterine tissue, and wherein the indicator mechanism generates an electrical signal responsive to which the energy delivery surface is activated.
In accordance with additional embodiments, an electrosurgical system for treating uterine tissue is provided, comprising an expandable dielectric member for positioning in a uterine cavity; and an indicator mechanism configured to indicate shapes of the dielectric member between non-expanded and expanded.
In accordance with additional embodiments, a system for treating uterine tissue is provided, comprising an expandable RF energy delivery surface for positioning in a uterine cavity; an RF source and controller configured to deliver current across the surface when the energy delivery surface is expanded in a uterine cavity; and a sensor mechanism for sensing the degree of expansion of the surface.
Further embodiments provide a system for treating uterine tissue, comprising an expandable RF energy delivery surface for positioning in a uterine cavity; an RF source configured to deliver current across the surface; and a lock-out mechanism for disabling the RF source until the surface has expanded to a threshold parameter.
In still further embodiments, a method of treating uterine tissue is provided, comprising expanding a RF energy delivery surface comprising a dielectric within a uterine cavity; and sensing the degree of expansion of the surface.
Still more embodiments provide a method of endometrial ablation, comprising positioning an expandable dielectric structure in a uterine cavity, the dielectric structure coupled to an electrosurgical energy source; moving the dielectric structure from a non-expanded shape to an expanded shape; acquiring a signal from an indicator mechanism indicating whether the dielectric structure has expanded to a threshold expanded shape; and activating the electrosurgical energy source if the dielectric structure has a threshold expanded shape.
For a fuller understanding of the nature and advantages of the present invention, reference should be made to the ensuing detailed description and accompanying drawings.
In order to better understand the invention and to see how it may be carried out in practice, some preferred embodiments are next described, by way of non-limiting examples only, with reference to the accompanying drawings, in which like reference characters denote corresponding features consistently throughout similar embodiments in the attached drawings.
In the following description, various embodiments of the present invention will be described. For purposes of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the embodiments. However, it will also be apparent to one skilled in the art that the present invention may be practiced without the specific details. Furthermore, well-known features may be omitted or simplified in order not to obscure the embodiment being described.
In general, an electrosurgical ablation system is described herein that comprises an elongated introducer member for accessing a patient's uterine cavity with a working end that deploys an expandable thin-wall dielectric structure containing an electrically non-conductive gas as a dielectric. In one embodiment, an interior chamber of the thin-wall dielectric structure contains a circulating neutral gas such as argon. An RF power source provides current that is coupled to the neutral gas flow by a first polarity electrode disposed within the interior chamber and a second polarity electrode at an exterior of the working end. The gas flow, which is converted to a conductive plasma by an electrode arrangement, functions as a switching mechanism that permits current flow to engaged endometrial tissue only when the voltage across the combination of the gas, the thin-wall dielectric structure and the engaged tissue reaches a threshold that causes capacitive coupling across the thin-wall dielectric material. By capacitively coupling current to tissue in this manner, the system provides a substantially uniform tissue effect within all tissue in contact with the expanded dielectric structure. Further, the invention allows the neutral gas to be created contemporaneously with the capacitive coupling of current to tissue.
In general, this disclosure may use the terms “plasma,” “conductive gas” and “ionized gas” interchangeably. A plasma consists of a state of matter in which electrons in a neutral gas are stripped or “ionized” from their molecules or atoms. Such plasmas can be formed by application of an electric field or by high temperatures. In a neutral gas, electrical conductivity is non-existent or very low. Neutral gases act as a dielectric or insulator until the electric field reaches a breakdown value, freeing the electrons from the atoms in an avalanche process thus forming a plasma. Such a plasma provides mobile electrons and positive ions, and acts as a conductor which supports electric currents and can form spark or arc. Due to their lower mass, the electrons in a plasma accelerate more quickly in response to an electric field than the heavier positive ions, and hence carry the bulk of the current.
Referring to
In an embodiment, an expandable-collapsible frame assembly 155 is disposed in the interior chamber. Alternatively, the dielectric structure may be expanded by a neutral gas without a frame, but using a frame offers a number of advantages. First, the uterine cavity is flattened with the opposing walls in contact with one another. Expanding a balloon-type member may cause undesirable pain or spasms. For this reason, a flat structure that is expanded by a frame is better suited for deployment in the uterine cavity. Second, in embodiments herein, the neutral gas is converted to a conductive plasma at a very low pressure controlled by gas inflows and gas outflows—so that any pressurization of a balloon-type member with the neutral gas may exceed a desired pressure range and would require complex controls of gas inflows and gas outflows. Third, as described below, the frame provides an electrode for contact with the neutral gas in the interior chamber 152 of the dielectric structure 150, and the frame 155 extends into all regions of the interior chamber to insure electrode exposure to all regions of the neutral gas and plasma. The frame 155 can be constructed of any flexible material with at least portions of the frame functioning as spring elements to move the thin-wall structure 150 from a collapsed configuration (
As will be described further below, the bore 175 in sleeve 115 and bore 180 in secondary translatable sleeve 170 function as gas outflow and gas inflow lumens, respectively. It should be appreciated that the gas inflow lumen can comprise any single lumen or plurality of lumens in either sleeve 115 or sleeve 170 or another sleeve, or other parts of the frame 155 or the at least one gas flow lumen can be formed into a wall of dielectric structure 150. In
It can be understood from
As will be described below, the working end embodiment of
In one embodiment, the gas inflow source 140A comprises one or more compressed gas cartridges that communicate with flexible conduit 136 through plug-in connector 137 and receiving connector 138 in the control unit 135 (
Now turning to the electrosurgical aspects of the invention,
Referring back to
The box diagrams of
More in particular,
In
In another embodiment, the system can include an electrode arrangement in the handle 106 or within the gas inflow channel to pre-ionize the neutral gas flow before it reaches the interior chamber 152. For example, the gas inflow channel can be configured with axially or radially spaced apart opposing polarity electrodes configured to ionize the gas inflow. Such electrodes would be connected in separate circuitry to an RF source. The first and second electrodes 215 (+) and 220 (−) described above would operate as described above to provide the current that is capacitively coupled to tissue through the walls of the dielectric structure 150. In all other respects, the system and method would function as described above.
Now turning to
In another aspect of the invention,
For example, in
By using the initial delivery of RF energy through the dielectric structure 150 and contacted tissue in the first, initial constant power mode, a voltage level is recorded (e.g., in the example, at one second) that directly relates to a combination of (i) the surface area of the dielectric structure, and the degree to which wall portions of the dielectric structure have been elastically stretched; (ii) the flow rate of neutral gas through the dielectric structure and (iii) the impedance of the contacted tissue. By then selecting a constant voltage for the second, constant voltage mode that is directly related to the recorded voltage from the first time interval, the length of the second, treatment interval can be the same for all different dimension uterine cavities and will result in substantially the same ablation depth, since the constant voltage maintained during the second interval will result in power that drifts off to lower levels toward the end of the treatment interval as tissue impedance increases. As described above, the controller 130A also can use an impedance level or a selected increase in impedance to terminate the treatment interval.
The algorithm above provides a recorded voltage at set time point in the first mode of RF energy application, but another embodiment can utilize a recorded voltage parameter that can be an average voltage over a measuring interval or the like. Also, the constant voltage in the second mode of RF energy application can include any ramp-up or ramp-down in voltage based on the recorded voltage parameter.
In general, an electrosurgical method for endometrial ablation comprises positioning a RF ablation device in contact with endometrial tissue, applying radiofrequency energy in a first mode based on a predetermined constant power over a first interval, and applying radiofrequency energy in a second mode over a second interval to ablate endometrial tissue, the energy level of the second mode being based on treatment voltage parameters obtained or measured during the first interval. Power during the first interval is constant, and during the second period is varied to maintain voltage at a constant level. Another step in applying RF energy in the first mode includes the step of recording a voltage parameter in the first interval, wherein the voltage parameter is at least one of voltage at a point in time, average voltage over a time interval, and a change or rate of change of voltage. The second mode includes setting the treatment voltage parameters in relation to the voltage parameter recorded in the first interval.
Referring to
In another aspect, the invention comprises a radiofrequency power supply, a means for coupling the radiofrequency power supply to an ablation device configured for positioning in a uterine cavity, the ablation device comprising a dielectric for contacting endometrial tissue, a system for recording an electrical parameter of the ablation device and contacted tissue, and a feedback system for varying the application of radiofrequency energy to tissue between a constant power mode and a constant voltage mode based on a recorded electrical parameter.
In another embodiment of the invention,
Referring to
In one aspect of the invention, it is important for the system and physician to understand the degree to which the dielectric structure 150 and frame 155 has expanded in the uterine cavity. If the dielectric structure 155 has not expanded to a significant degree, it may indicate that the uterine cavity is very small or very narrow, that fibroids are impinging on dielectric structure preventing its expansion, that the uterine cavity is very asymmetric, or that a tip of the dielectric structure and frame 155 has penetrated into an endometrial layer, perforated the uterine wall or followed a dissection path created by a sounding procedure just prior to deployment of the dielectric structure. Further, in one system embodiment, the dielectric structure 150 is preferred to have a minimum surface area directly related to its expanded shape to thus cooperate with an RF energy delivery algorithm.
In one embodiment, the system provides a “degree of frame-open” signaling mechanism for signaling the physician that the frame 155 and dielectric structure 150 has expanded to a minimum predetermined configuration. The signaling mechanism is based on the relative axial location of inner sleeve 170 and sleeve 115 as can be understood from FIGS. 12 and 13A-13B. In
In another aspect of the invention also depicted in
The embodiment of
In
In general, a system of the invention comprises an energy-delivery structure moveable between non-expanded and expanded shapes wherein the expanded shape is configured for positioning in a uterine cavity, a Hall effect sensor carried in a first peripheral portion of the structure in an expanded shape and a magnet carried by a second portion of the structure. The magnet can be carried in a peripheral portion that opposes the Hall sensor. Alternatively, the magnet can be carried in a central portion of the structure when in an expanded shape.
In another embodiment, the system can comprise an expandable-collapsible energy-delivery structure that carries a plurality of Hall effect sensors. Such Hall sensors can be carried in opposing peripheral portions of the working end.
In general, an embodiment, system of the invention can use permanent magnets (such as rare earth magnets) or electromagnets to cooperate with the Hall effect sensor.
In another aspect of the invention, the ablation system comprises a thin wall expandable structure having an interior chamber and a Hall effect sensor and magnetic means carried in first and second locations in or about the structure wherein the sensor provides a signal of movement of the magnet away from the sensor upon expansion of the expandable structure to thereby indicate an expansion parameter of the structure. The structure can be expandable by means of a frame as described above or by an inflation medium.
In general, the scope of the invention extends to expandable working end for endometrial ablation that utilize any energy delivery means, such as RF means described above, bi-polar or mono-polar electrode means, microwave means etc. In all these cases, it may be useful or necessary to determine the dimensional parameters of the working to insure that it opened properly or to determine uterine cavity dimensions to thereby determine energy delivery parameters.
A method of the invention for characterizing a uterine cavity comprises transcervically introducing a working end into a patient uterus and expanding an expandable-collapsible structure carrying at least one Hall effect sensor and magnet, wherein the Hall effect sensor varies its output in response to a change the magnetic field to provide a signal indicative of a dimensional parameter of the uterine cavity. The sensing system can be adapted to generate a signal indicating a frame-open parameter, or volume, width or length of the uterine cavity. The system and method can further include acquiring the signal from the Hall effect sensor to select a parameter of ablative energy delivery from the working end for endometrial ablation.
Although particular embodiments of the present invention have been described above in detail, it will be understood that this description is merely for purposes of illustration and the above description of the invention is not exhaustive. Specific features of the invention are shown in some drawings and not in others, and this is for convenience only and any feature may be combined with another in accordance with the invention. A number of variations and alternatives will be apparent to one having ordinary skills in the art. Such alternatives and variations are intended to be included within the scope of the claims. Particular features that are presented in dependent claims can be combined and fall within the scope of the invention. The invention also encompasses embodiments as if dependent claims were alternatively written in a multiple dependent claim format with reference to other independent claims.
Other variations are within the spirit of the present invention. Thus, while the invention is susceptible to various modifications and alternative constructions, certain illustrated embodiments thereof are shown in the drawings and have been described above in detail. It should be understood, however, that there is no intention to limit the invention to the specific form or forms disclosed, but on the contrary, the intention is to cover all modifications, alternative constructions, and equivalents falling within the spirit and scope of the invention, as defined in the appended claims.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. The term “connected” is to be construed as partly or wholly contained within, attached to, or joined together, even if there is something intervening. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate embodiments of the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
This application claims the benefit of U.S. Provisional Application No. 61/366,268, filed Jul. 21, 2010, the full disclosure of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4611604 | Botvidsson et al. | Sep 1986 | A |
4949718 | Neuwirth et al. | Aug 1990 | A |
4979948 | Geddes et al. | Dec 1990 | A |
5045056 | Behl | Sep 1991 | A |
5078717 | Parins | Jan 1992 | A |
5084044 | Quint | Jan 1992 | A |
5191883 | Lennox et al. | Mar 1993 | A |
5242390 | Goldrath | Sep 1993 | A |
5248312 | Langberg | Sep 1993 | A |
5277201 | Stern | Jan 1994 | A |
5344435 | Turner et al. | Sep 1994 | A |
5374261 | Yoon | Dec 1994 | A |
5401272 | Perkins | Mar 1995 | A |
5441498 | Perkins | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5501681 | Neuwirth et al. | Mar 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5549546 | Schneider et al. | Aug 1996 | A |
5558672 | Edwards | Sep 1996 | A |
5562703 | Desai | Oct 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
5575788 | Baker et al. | Nov 1996 | A |
5584872 | LaFontaine et al. | Dec 1996 | A |
5599347 | Hart et al. | Feb 1997 | A |
5653692 | Masterson et al. | Aug 1997 | A |
5681308 | Edwards et al. | Oct 1997 | A |
5697281 | Eggers | Dec 1997 | A |
5697882 | Eggers | Dec 1997 | A |
5713942 | Stern et al. | Feb 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5769880 | Truckai et al. | Jun 1998 | A |
5800493 | Stevens et al. | Sep 1998 | A |
5827273 | Edwards | Oct 1998 | A |
5843020 | Tu et al. | Dec 1998 | A |
5846239 | Swanson et al. | Dec 1998 | A |
5860974 | Abele | Jan 1999 | A |
5876340 | Tu et al. | Mar 1999 | A |
5891094 | Masterson et al. | Apr 1999 | A |
5891134 | Goble et al. | Apr 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5902251 | vanHooydonk | May 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5925038 | Panescu et al. | Jul 1999 | A |
5954714 | Saadat et al. | Sep 1999 | A |
5964755 | Edwards | Oct 1999 | A |
5976129 | Desai | Nov 1999 | A |
5997534 | Tu et al. | Dec 1999 | A |
6024743 | Edwards | Feb 2000 | A |
6026331 | Feldberg et al. | Feb 2000 | A |
6041260 | Stern et al. | Mar 2000 | A |
6057689 | Saadat | May 2000 | A |
6086581 | Reynolds et al. | Jul 2000 | A |
6113597 | Eggers et al. | Sep 2000 | A |
6139570 | Saadat et al. | Oct 2000 | A |
6146378 | Mikus et al. | Nov 2000 | A |
6149620 | Baker et al. | Nov 2000 | A |
6228078 | Eggers et al. | May 2001 | B1 |
6254599 | Lesh et al. | Jul 2001 | B1 |
6283962 | Tu et al. | Sep 2001 | B1 |
6296639 | Truckai et al. | Oct 2001 | B1 |
6302904 | Wallsten et al. | Oct 2001 | B1 |
6315776 | Edwards et al. | Nov 2001 | B1 |
6366818 | Bolmsjo | Apr 2002 | B1 |
6387088 | Shattuck et al. | May 2002 | B1 |
6395012 | Yoon et al. | May 2002 | B1 |
6416508 | Eggers et al. | Jul 2002 | B1 |
6416511 | Lesh et al. | Jul 2002 | B1 |
6443947 | Marko et al. | Sep 2002 | B1 |
6508815 | Strul et al. | Jan 2003 | B1 |
6551310 | Ganz et al. | Apr 2003 | B1 |
6589237 | Woloszko et al. | Jul 2003 | B2 |
6602248 | Sharps et al. | Aug 2003 | B1 |
6607545 | Kammerer et al. | Aug 2003 | B2 |
6635054 | Fjield et al. | Oct 2003 | B2 |
6635055 | Cronin | Oct 2003 | B1 |
6663626 | Truckai et al. | Dec 2003 | B2 |
6673071 | VanDusseldorp et al. | Jan 2004 | B2 |
6699241 | Rappaport et al. | Mar 2004 | B2 |
6726684 | Woloszko et al. | Apr 2004 | B1 |
6736811 | Panescu et al. | May 2004 | B2 |
6746447 | Davison et al. | Jun 2004 | B2 |
6758847 | Maguire | Jul 2004 | B2 |
6780178 | Palanker et al. | Aug 2004 | B2 |
6802839 | Behl | Oct 2004 | B2 |
6813520 | Truckai et al. | Nov 2004 | B2 |
6814730 | Li | Nov 2004 | B2 |
6832996 | Woloszko et al. | Dec 2004 | B2 |
6837887 | Woloszko et al. | Jan 2005 | B2 |
6840935 | Lee | Jan 2005 | B2 |
6872205 | Lesh et al. | Mar 2005 | B2 |
6896674 | Woloszko et al. | May 2005 | B1 |
6923805 | LaFontaine et al. | Aug 2005 | B1 |
6929642 | Xiao et al. | Aug 2005 | B2 |
6949096 | Davison et al. | Sep 2005 | B2 |
6951569 | Nohilly et al. | Oct 2005 | B2 |
6954977 | Maguire et al. | Oct 2005 | B2 |
6960203 | Xiao et al. | Nov 2005 | B2 |
7025765 | Balbierz et al. | Apr 2006 | B2 |
7074217 | Strul et al. | Jul 2006 | B2 |
7083614 | Fijeld et al. | Aug 2006 | B2 |
7087052 | Sampson et al. | Aug 2006 | B2 |
7118590 | Cronin | Oct 2006 | B1 |
7179255 | Lettice et al. | Feb 2007 | B2 |
7186234 | Dahla et al. | Mar 2007 | B2 |
7192430 | Truckai et al. | Mar 2007 | B2 |
7238185 | Palanker et al. | Jul 2007 | B2 |
7270658 | Woloszko et al. | Sep 2007 | B2 |
7276063 | Davison et al. | Oct 2007 | B2 |
7294126 | Sampson et al. | Nov 2007 | B2 |
7297143 | Woloszko et al. | Nov 2007 | B2 |
7326201 | Fijeld et al. | Feb 2008 | B2 |
7331957 | Woloszko et al. | Feb 2008 | B2 |
RE40156 | Sharps et al. | Mar 2008 | E |
7371231 | Rioux et al. | May 2008 | B2 |
7371235 | Thompson et al. | May 2008 | B2 |
7381208 | van der Walt et al. | Jun 2008 | B2 |
7387628 | Behl et al. | Jun 2008 | B1 |
7407502 | Strul et al. | Aug 2008 | B2 |
7419500 | Marko et al. | Sep 2008 | B2 |
7452358 | Stern et al. | Nov 2008 | B2 |
7462178 | Woloszko et al. | Dec 2008 | B2 |
7500973 | Vancelette et al. | Mar 2009 | B2 |
7512445 | Truckai et al. | Mar 2009 | B2 |
7530979 | Ganz et al. | May 2009 | B2 |
7549987 | Shadduck | Jun 2009 | B2 |
7556628 | Utley et al. | Jul 2009 | B2 |
7572251 | Davison et al. | Aug 2009 | B1 |
7604633 | Truckai et al. | Oct 2009 | B2 |
7625368 | Schechter et al. | Dec 2009 | B2 |
7674259 | Shadduck | Mar 2010 | B2 |
7678106 | Lee | Mar 2010 | B2 |
7708733 | Sanders et al. | May 2010 | B2 |
7717909 | Strul et al. | May 2010 | B2 |
7736362 | Eberl et al. | Jun 2010 | B2 |
7749159 | Crowley et al. | Jul 2010 | B2 |
7824405 | Woloszko et al. | Nov 2010 | B2 |
7846160 | Payne et al. | Dec 2010 | B2 |
7879034 | Woloszko et al. | Feb 2011 | B2 |
7918795 | Grossman | Apr 2011 | B2 |
8328798 | Witzel et al. | Dec 2012 | B2 |
20020022870 | Truckai et al. | Feb 2002 | A1 |
20020068934 | Edwards et al. | Jun 2002 | A1 |
20020082635 | Kammerer et al. | Jun 2002 | A1 |
20030153905 | Edwards et al. | Aug 2003 | A1 |
20030171743 | Tasto et al. | Sep 2003 | A1 |
20030208200 | Palanker et al. | Nov 2003 | A1 |
20040002702 | Xiao et al. | Jan 2004 | A1 |
20040087936 | Stern et al. | May 2004 | A1 |
20040215180 | Starkebaum et al. | Oct 2004 | A1 |
20040215182 | Lee | Oct 2004 | A1 |
20040215296 | Ganz et al. | Oct 2004 | A1 |
20040230190 | Dahla et al. | Nov 2004 | A1 |
20050143728 | Sampson et al. | Jun 2005 | A1 |
20050165389 | Swain et al. | Jul 2005 | A1 |
20050182397 | Ryan | Aug 2005 | A1 |
20050192652 | Cioanta et al. | Sep 2005 | A1 |
20050240176 | Oral et al. | Oct 2005 | A1 |
20050240211 | Sporri et al. | Oct 2005 | A1 |
20050251131 | Lesh | Nov 2005 | A1 |
20060009756 | Francischelli et al. | Jan 2006 | A1 |
20060052771 | Sartor et al. | Mar 2006 | A1 |
20060089637 | Werneth et al. | Apr 2006 | A1 |
20060189971 | Tasto et al. | Aug 2006 | A1 |
20060189976 | Karni et al. | Aug 2006 | A1 |
20060224154 | Shadduck et al. | Oct 2006 | A1 |
20060259025 | Dahla | Nov 2006 | A1 |
20070021743 | Rioux et al. | Jan 2007 | A1 |
20070083192 | Welch | Apr 2007 | A1 |
20070156138 | Eisele | Jul 2007 | A1 |
20070161981 | Sanders et al. | Jul 2007 | A1 |
20070213704 | Truckai et al. | Sep 2007 | A1 |
20070282323 | Woloszko et al. | Dec 2007 | A1 |
20070287996 | Rioux | Dec 2007 | A1 |
20070288075 | Dowlatshahi | Dec 2007 | A1 |
20070293853 | Truckai et al. | Dec 2007 | A1 |
20080058797 | Rioux | Mar 2008 | A1 |
20080097425 | Truckai | Apr 2008 | A1 |
20080125765 | Berenshteyn et al. | May 2008 | A1 |
20080125770 | Kleyman | May 2008 | A1 |
20080154238 | McGuckin | Jun 2008 | A1 |
20080167664 | Payne et al. | Jul 2008 | A1 |
20080208189 | Van Wyk et al. | Aug 2008 | A1 |
20080221567 | Sixto, Jr. | Sep 2008 | A1 |
20080249518 | Warnking et al. | Oct 2008 | A1 |
20090048593 | Ganz et al. | Feb 2009 | A1 |
20090052488 | Sugiyama et al. | Feb 2009 | A1 |
20090054892 | Rioux et al. | Feb 2009 | A1 |
20090076494 | Azure | Mar 2009 | A1 |
20090105703 | Shadduck | Apr 2009 | A1 |
20090131927 | Kastelein et al. | May 2009 | A1 |
20090149846 | Hoey et al. | Jun 2009 | A1 |
20090163908 | MacLean et al. | Jun 2009 | A1 |
20090209956 | Marion | Aug 2009 | A1 |
20090306654 | Garbagnati | Dec 2009 | A1 |
20100004595 | Nguyen et al. | Jan 2010 | A1 |
20100036372 | Truckai et al. | Feb 2010 | A1 |
20100042095 | Bigley et al. | Feb 2010 | A1 |
20100042097 | Newton et al. | Feb 2010 | A1 |
20100049190 | Long et al. | Feb 2010 | A1 |
20100100091 | Truckai et al. | Apr 2010 | A1 |
20100100094 | Truckai et al. | Apr 2010 | A1 |
20100106152 | Truckai et al. | Apr 2010 | A1 |
20100114089 | Truckai et al. | May 2010 | A1 |
20100121319 | Chu et al. | May 2010 | A1 |
20100125269 | Emmons et al. | May 2010 | A1 |
20100137855 | Berjano Zanon et al. | Jun 2010 | A1 |
20100137857 | Shroff et al. | Jun 2010 | A1 |
20100152725 | Pearson et al. | Jun 2010 | A1 |
20100185191 | Carr et al. | Jul 2010 | A1 |
20100198214 | Layton et al. | Aug 2010 | A1 |
20100204688 | Hoey et al. | Aug 2010 | A1 |
20100217256 | Strul et al. | Aug 2010 | A1 |
20100228239 | Freed | Sep 2010 | A1 |
20100228245 | Sampson et al. | Sep 2010 | A1 |
20100286680 | Kleyman | Nov 2010 | A1 |
20110004205 | Chu et al. | Jan 2011 | A1 |
20110060391 | Unetich et al. | Mar 2011 | A1 |
20110112524 | Stern et al. | May 2011 | A1 |
Number | Date | Country |
---|---|---|
1 236 440 | Sep 2002 | EP |
WO 2011053599 | May 2011 | WO |
Entry |
---|
Third party observations dated Sep. 6, 2013 for EP Application No. 10830743.0. |
Number | Date | Country | |
---|---|---|---|
20120022520 A1 | Jan 2012 | US |
Number | Date | Country | |
---|---|---|---|
61366268 | Jul 2010 | US |